@article{ceb45c467ca14349b69b3d8ad8451b56,
title = "Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: A retrospective analysis of the Canadian ENHANCE cohort",
author = "Hodder, {Richard V.} and Richard Hall and Russell, {James A.} and Fisher, {Harold N.} and Bobbie Lee",
note = "Funding Information: Eli Lilly and Company sponsored the international ENHANCE trial and contributed to the publication costs of this manuscript. RVH and RH have received consulting and speaker reimbursements from a number of industry groups including Eli Lilly Canada. RVH, RH, and JAR have received investigator payments for the conduct of the ENHANCE trial, but have no financial interests in Eli Lilly or any of its products. JAR reports receiving consulting fees from Ferring, which manufactures vasopressin, and from Sirius Genomics Inc. JAR also reports receiving grant support from Sirius Genomics, Novartis, and Eli Lilly. HNF is an employee of Eli Lilly Canada and BL was an employee of Eli Lilly Canada at the time of the research and manuscript preparation. HNF holds shares in Eli Lilly Canada. JAR reports holding stock in Sirius Genomics Incorporated, which has submitted patents owned by the University of British Columbia and licensed to Sirius Genomics, that are related to the genetics of vasopressin and protein C. The University of British Columbia has also submitted a patent related to the use of vasopressin in septic shock. JAR reports being an inventor on these patents.",
year = "2009",
month = may,
day = "20",
doi = "10.1186/cc7893",
language = "English",
volume = "13",
journal = "Critical Care",
issn = "1364-8535",
publisher = "Springer Science + Business Media",
number = "3",
}